ClinicalTrials.gg
RecruitingNCT03721783Updated Oct 26, 2024

Infant and Child European Cryoablation Project ICECaP

An observational study in Therapy, Soft Tissue Lesion and Cryoablation, sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust · Observational

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
Up to 18 Years
Sex
All
01

Study summary

A registry to audit the current range of applications, technical success rate, safety profile, complication rate and efficacy of cryoablation procedures being performed in children.

Read the detailed description

Cryoablation involves image-guided insertion of single-use specialised needles or probes through the skin into a soft tissue or bone lesion. A mechanised unit is connected to the probe(s) and generates cyclical freezing and thawing of the tissues at the probe tip(s) via exchange of highly pressurised gases through the probe lumen(s), utilising the Joules-Thomson effect. Extreme freezing and thawing of the lesion causes permanent tissue destruction through both mechanical disruption of tissue membranes and a secondary immune response effect.

Cryoablation is one of several minimally invasive ablative techniques used to reduce the size of or to eradicate soft tissue and bone lesions. Ablative techniques are now an accepted standard of care for many benign and malignant lesions in adult practice. Cryoablation is widely used in the management of renal cell carcinoma, with medium-term outcomes matching surgical resection.

The advantages of cryoablation over surgery, particularly in a paediatric population, are:

  • Minimally invasive approach, therefore suitable for day case procedures and almost scarless
  • Significantly faster recovery times compared to complex surgical debulking
  • Minimal complication rates compared to surgery (less risk to nerves, blood vessels and critical solid organ)
  • Affords excellent pain relief (has an independent role in chronic pain management)

To date the use of cryoablation in children remains novel and under reported.

The purpose of this registry is to audit the current range of applications, technical success rate, safety profile, complication rate and efficacy of cryoablation procedures in children. This registry would, as a minimum, clarify current practice and outcomes within individual centres, allowing teams to audit and benchmark their own procedures and aiming to align practice amongst individual hospitals. A registry would aim to generate a body of evidence to establish parameters for best practice and may highlight conditions that respond better or worse than others to this novel therapy. The audit may lead to a clinical trial for the treatment of one or more specific conditions but in the interim would provide evidence for the efficacy and safety of the procedure and will aim to protect against indiscriminate use of this treatment modality in children in the future.

Registry design: This is a prospective multi-centre, open, non-controlled repeat treatment registry and data collection in collaboration with individual hospitals in the UK and Europe.

The proposal is for a robust, multi-centre data collection system to support and establish the treatment pathway, safety parameters and outcomes of paediatric cryoablation. The number of procedures performed in each centre will be understandably small, given the specialist nature of this emerging modality and the small numbers of patients being offered this treatment. The registry aims to collect standardised data from all centres performing cryoablation in children to allow robust audit of this procedure. Multiple data sets will be collected and entered into an anonymised web based host.

Upon completion of recruitment and follow up, the data will be subject to uni-variate and multi-variate analysis.

The registry is designed with the patient at the centre of the data collection and outcomes. Anonymised data will be analysed collectively but will ultimately be owned and retained by individual trusts. Details of the full data set proposed are detailed in the attached study protocol.

02

Conditions studied

  • Therapy
  • Soft Tissue Lesion
  • Cryoablation
  • Pediatric

Keywords

  • cryoablation
  • pediatric
  • registry
03

In context

Lead sponsor

Great Ormond Street Hospital for Children NHS Foundation Trust is the lead sponsor of 82 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All children in whom a clinical decision is made to treat with percutaneous cryoablation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all children in whom a clinical decision is made to treat with percutaneous cryoablation, to include those in whom cryoablation was not technically or clinically possible at any stage.

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • children with soft tissue lesions

    All children who undergo cryoablation therapy for benign soft tissue lesions

    Procedure: Cryoablation

Interventions

  • ProcedureCryoablation

    Image guided cryoablation therapy of soft tissue lesions

06

What researchers measure

Primary outcomes

  1. Occurrence and severity of complications arising from cryoablation treatment

    Documentation and severity scoring of any complications arising from a cryoablation procedure, using the Society of Interventional Radiology (SIR) standards of practice committee classification of complications by outcome scoring system. The range of the outcome scoring system is A-F, with A being the least severe (no therapy, no consequence), and F being the most severe (resulting death). \[Omary et al. J Vasc Interv Radiol 2003; 14:S293-S295\]

    Time frame: 2 years

Secondary outcomes

  1. Change in maximal diameter of lesion following treatment

    In patients where this is applicable, measure change in maximal lesion diameter on ultrasound or MRI imaging, comparing baseline (pre-treatment) lesion diameter to (post treatment) lesion diameter at 2 years. Subsequent lesion measurements will be made annually up to 5 years (for patients included in follow up).

    Time frame: 5 years

  2. Change in symptomatology following treatment

    Where applicable, measure change in symptomatology post treatment, as assessed by PedsQL Pediatric Quality of Life Inventory UK questionnaire version 4.0. This is a scored questionnaire used for the assessment of physical functioning, emotional functioning, social functioning and school functioning. It is completed by both the child (child report) and the parent (parent report). Each questionnaire consists of 23 items graded 0-4 where 0 equates to no functional deficit and a maximum achievable score of 92 equates to the most severe functional deficit. Combined parent and child reports are collated to give a range of scores of 0-184 per assessment.

    Time frame: 2 years

  3. Procedure failure

    This is a composite outcome defined as having the presence of any (or all) of the following: absence of consent, patient not fit for procedure, clinical complication, technical failure of equipment. This data will be collected over the 3 years of procedure recruitment into the registry.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Shaikh R, Alomari AI, Kerr CL, Miller P, Spencer SA. Cryoablation in fibro-adipose vascular anomaly (FAVA): a minimally invasive treatment option. Pediatr Radiol. 2016 Jul;46(8):1179-86. doi: 10.1007/s00247-016-3576-0. Epub 2016 Feb 22. PubMed 26902298 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — This is planned as a multi centre registry, as there are other IR centres within the UK and Europe that wish to contribute paediatric data. This would be welcomed, to increase numbers and strengthen the outcome data

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03721783
Lead sponsor
Great Ormond Street Hospital for Children NHS Foundation Trust
Responsible party
Sponsor
First posted
Oct 26, 2018
Start date
Jun 24, 2021
Primary completion
Feb 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 26, 2024

Study contacts

Alex Barnacle, BM
Contact
Alex.Barnacle@gosh.nhs.uk
+447810792517
Premal Patel, BM
Contact
Premal.Patel@gosh.nhs.uk
+442078297943
Alex Barnacle, BM
principal investigator · Great Ormond Street Hospital, London, UK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion